Cyclooxygenase-2: A therapeutic target for prostate cancer

Clinical Genitourinary Cancer

Volumn 4, Issue 3, 2005, Pages 203-211

  Pruthi, Raj S ^a   Wallen, Eric M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Angiogenesis; Dietary supplements; Prostaglandins

Indexed keywords

ANDROGEN; BENZO[A]PYRENE; CELECOXIB; CONJUGATED LINOLEIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIGALLOCATECHIN GALLATE; FISH OIL; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RAS PROTEIN; ROFECOXIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VALDECOXIB; WNT PROTEIN; ANTINEOPLASTIC AGENT;

ADENOMATOUS POLYP; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INVASION; CARCINOGENESIS; CARDIOVASCULAR EFFECT; CELL MOTILITY; CELL STRAIN LNCAP; CLINICAL TRIAL; DIET SUPPLEMENTATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; MOUSE; MUTAGENESIS; NONHUMAN; PROPHYLAXIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SYSTEMATIC REVIEW; BIOSYNTHESIS; DRUG EFFECT; MALE; PHYSIOLOGY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 33644937873     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.034     Document Type: Article

References (85)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232-235.
2. Needleman P, Turk J, Jakschik BA, et al. Arachidonic acid metabolism. Annu Rev Biochem 1986; 55:69-102.
3. Otto JC, Smith WL. Prostaglandin endoperoxide synthases-1 and -2. J Lipid Mediat Cell Signal 1995; 12:139-156.
4. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anti-cancer properties. Cancer Control 2002; 9(2 suppl):28-35.
5. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271:33157-33160.
6. Futaki N, Takahashi S, Yokoyama M, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47:55-59.
7. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30:3-8.
8. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002; 53:35-41.
9. Appleby SB, Ristimaki A, Neilson K, et al. Structure of the human cyclooxygenase-2 gene. Biochem J 1994; 302:723-727.
10. Almer G, Guegan C, Teismann P, et al. Increased expression of the proinflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol 2001; 49:176-180.
11. Halliday G, Robinson SR, Shepherd C, et al. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 2000; 27:1-7.
12. Castrop H, Schweda F, Schumacher K, et al. Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol 2001; 12:867.
13. Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor [published erratum appears in Am J Ther 2000; 7:341]. Am J Ther 2000; 7:159-175.
14. Brzozowski T, Konturek PC, Konturek SJ, et al. Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor. J Physiol Pharmacol 2000; 51:751-773.
15. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001; 8:97-114.
16. Subbaramaiah K, Altorki N, Chung WJ, et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274:10911-10915.
17. Fossilen E. Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001; 31:325-348.
18. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164:820-823.
19. Richter M, Weiss M, Weinberger I, et al. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001; 22:17-22.
20. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89:2637-2640.
21. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99:2254-2257.
22. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6:135-139.
23. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in die angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6:4739-4741.
24. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem 2000; 7:1163-1169.
25. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60:1306-1311.
26. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716.
27. Daniel TO, Liu H, Morrow JD, et al. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999; 59:4574-4577
28. Lu X, Xie W, Reed D, et al. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. PTOC Natl Acad Sci U S A 1995; 92:7961-7964.
29. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190:279-287.
30. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58:362-365.
31. Chan TA, Morin PJ, Vogelstein B, et al. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A 1998; 95:681-687.
32. Cao Y, Pearman AT, Zimmerman GA, et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci U S A 2000; 97:11280-11285.
33. Chen JK, Capdevila J, Harris RC. Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol 2001; 21:6322-6331.
34. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83:493-501.
35. Johnson AJ, Hsu AL, Lin HP, et al. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 2002; 366:831-837.
36. Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NF-kappa B pathway. J Biol Chem 1999; 274:27307-27310.
37. Hsu AL, Ching TT, Wang DS, et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275:11397-11402.
38. Ballif BA, Mincek NV, Barratt JT, et al. Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. Proc Natl Acad Sci U S A 1996; 93:5544-5547.
39. Kimura M, Osumi S, Ogihara M. Stimulation of DNA synthesis and proliferation by prostaglandins in primary cultures of adult rat hepatocytes. Eur J Pharmacol 2000; 404:259-263.
40. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52:5575-5580.
41. Attiga FA, Fernandez PM, Weeraratna AT, et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000; 60:4629-4632.
42. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164:361-364.
43. Quarles LD, Haupt DM, Davidai G, et al. Prostaglandin F2 alpha-induced mitogenesis in MC3T3-E1 osteoblasts: role of protein kinase-C-mediated tyrosine phosphorylation. Endocrinology 1993; 132:1505-1509.
44. Chen WS, Wei SJ, Liu JM, et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001; 91:894-899.
45. Jiang MC, Liao CF, Lee PH. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun 2001; 282:671-677.
46. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001; 93:497-506.
47. Tomozawa S, Tsuno NH, Sunami E, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000; 83:324-328.
48. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 1996; 342:1946-1950.
49. Eastham JA, Mire E, Williams BJ. Cyclooxygenase-2 (COX-2) expression in primary and metastatic prostate cancer. J Urol 2000; 163(suppl):104 (Abstract #453).
50. Liu XH, Yao S, Kirschenbaum A, et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58:4245-4249.
51. de Leval X, Hanson J, David JL, et al. New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem 2004; 11:1243-1252.
52. Dogne JM, de Leval X, Hanson J, et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 2004; 11:1223-1241.
53. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102:840-845.
54. Dogne JM, de Levai X, Benoit P, et al. Recent advances in antiplatelet agents. Curr Med Chem 2002; 9:577-589.
55. Hermann M, Camici G, Fratton A, et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108:2308-2311.
56. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142:157-164.
57. Bresalier RS, Sandler RS, Quan H, et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102.
58. Solomon SD, McMurray JJ, Pfeffer MA, et al. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080.
59. FDA Public Health Advisory. FDA Announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available at: http://www.fda.gov/cder/ drug/advisory/COX2.htm. Accessed May 15, 2005.
60. Okie S. Raising the safety baræthe FDAs coxib meeting. N Engl J Med 2005; 352:1283-1285.
61. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77:219-224.
62. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000; 7:169-173.
63. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998; 77:511-516.
64. Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320:1642-1647.
65. Gupta S, Srivastava M, Ahmad N, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42:73-76.
66. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89:589-593.
67. Lee LM, Pan CC, Cheng CJ, et al. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001; 21:1291-1296.
68. Uotila P, Valve E, Martikainen P, et al. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001; 29:23-26.
69. Madaan S, Abel PD, Chaudhary KS, et al. Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000; 86:736-741.
70. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000; 56:671-676.
71. Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53:232-240.
72. Panguluri RC, Long LO, Chen W, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004; 25:961-966.
73. Kamijo T, Sato T, Nagatomi Y, et al. Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol 2001; 8(7 suppl):S35-S41.
74. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004; 64:3334-3343.
75. Derksen JE, Pruthi RS. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 2004; 93:275-278.
76. Pruthi RS, Derksen JE. A phase II trial of celecoxib in PSA-recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Proc Am Soc Clin Oncol 2004; 23:403 (Abstract #4593).
77. Dandekar DS, Lokeshwar BL. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 2004; 10:8037-8047.
78. Wen B, Deutsch E, Eschwege P, et al. Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells. J Urol 2003; 170:2036-2039.
79. Ohshiba T, Miyaura C, Ito A. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochem Biophys Res Commun 2003; 300:957-964.
80. Sabino MA, Ghilardi JR, Jongen JL, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002; 62:7343-7349.
81. Hussain T, Gupta S, Adhami VM, et al. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer 2005; 113:660-669.
82. Goldmann WH, Sharma AL, Currier SJ, et al. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int 2001; 25:1117-1124.
83. Kim HY, Yu R, Kim JS, et al. Antiproliferative crude soy saponin extract modulates the expression of IkappaBalpha, protein kinase C, and cyclooxygenase-2 in human colon cancer cells. Cancer Lett 2004; 210:1-6.
84. Pham H, Banerjee T, Ziboh VA. Suppression of cyclooxygenase-2 overexpression by 15S-hydroxyeicosatrienoic acid in androgen-dependent prostatic adenocarcinoma cells. Int J Cancer 2004; 111:192-197.
85. Baines A, Taylor-Parker M, Goulet AC, et al. Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines. Cancer Biol Ther 2002; 1:370-374.